Trial 2N-15-5


A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Chemotherapy: Local
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Barbara Gitlitz, M.D.
Other Trial Staff:  Gina Tse, R.N., Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Shandra Edwards, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.